Novartis AG (NVS)
NVS trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | NVS on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Switzerland |
| IPO year | Not reported by the screener |
| SEC CIK | 0001114448 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Switzerland |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-02-04 |
| Cash and burn | $11.4B cash; operating cash flow $4.8B a quarter. | Report 2025-12-31 |
| Shares outstanding | 1,908,151,679 (2025-12-31); 1,975,089,248 a year earlier; 2,119,609,057 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 4 424B5 takedowns | Latest 2026-11-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG AG, Basel, Switzerland | PCAOB Form AP 2026-03-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | $14.0B | $19.1B | $11.4B | $28.7B | Needs four quarters | 20-F 2026-02-04 |
| FY 2024 2024-12-31 | Not filed | $11.9B | $17.6B | $11.5B | $24.7B | Needs four quarters | 20-F 2026-02-04 |
| FY 2023 2023-12-31 | Not filed | $14.8B | $14.5B | $13.4B | $20.6B | Needs four quarters | 20-F 2026-02-04 |
| FY 2022 2022-12-31 | Not filed | $7.0B | $14.2B | $7.5B | $22.5B | Needs four quarters | 20-F 2025-01-31 |
| FY 2021 2021-12-31 | Not filed | $24.0B | $15.1B | $12.4B | $25.5B | Needs four quarters | 20-F 2024-01-31 |
| FY 2020 2020-12-31 | Not filed | $8.1B | $13.7B | $9.7B | $28.5B | Needs four quarters | 20-F/A 2023-05-15 |
| FY 2019 2019-12-31 | Not filed | $11.7B | $13.6B | $11.1B | $22.4B | Needs four quarters | 20-F 2022-02-02 |
| FY 2018 2018-12-31 | Not filed | $12.6B | $14.3B | $13.3B | $25.7B | Needs four quarters | 20-F 2021-01-26 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-10 |
| Latest annual report | 20-F | 2026-02-04 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.3% |
| 1 month | +12.7% |
| 3 months | +5.8% |
| Year to date | +16.4% |
| 1 year | +21.7% |
| From 52-week high | -4.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AZN | AstraZeneca PLC | $184.02 | -0.23% | $285.4B |
| MRK | Merck & Company Inc. Common Stock (new) | $144.46 | -2.23% | $356.1B |
| ABT | Abbott Laboratories | $107.45 | -0.99% | $186.1B |
| NVO | Novo Nordisk A/S | $41.60 | -0.07% | $184.2B |
| ABBV | AbbVie Inc. | $294.55 | -0.16% | $520.7B |
| PFE | Pfizer Inc. | $28.86 | -0.10% | $164.5B |
| JNJ | Johnson & Johnson | $282.55 | -1.12% | $680.2B |
| VRTX | Vertex Pharmaceuticals Incorporated | $537.79 | -0.15% | $136.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier